Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate

European Journal of Medicinal Chemistry

Volumn 82, Issue , 2014, Pages 293-307

  Song, Yu'Ning ^a   Lin, Xiaoqian ^a   Kang, Dongwei ^a   Li, Xiao ^a   Zhan, Peng ^a   Liu, Xinyong ^a   Zhang, Qingzhu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Anticancer agents; Apoptosis; CDC25 inhibitor; Cell cycle arrest; Reactive oxygen species

Indexed keywords

1,2,4 TRIAZOLE DERIVATIVE; ANTINEOPLASTIC AGENT; CHEQ 1; CHEQ 2; CHEQ 3; CHEQ 4; CHEQ 5; CHEQ 6; CYCLIN B; IMIDAZOPYRIDINE DERIVATIVE; MENADIONE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; THIOACETAMIDE DERIVATIVE; UNCLASSIFIED DRUG; XDW 1; 1-(3,4-DIHYDROXYPHENYL)-2-((1-MESITYL-1H-IMIDAZO(4,5-C)PYRIDIN-2-YL)THIO)ETHANONE; IMIDAZOLE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PYRIDAZINE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IC 50; LD 50; LIVER TUMOR; LOSS OF APPETITE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; S PHASE CELL CYCLE CHECKPOINT; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; HEPG2 CELL LINE; HT 29 CELL LINE; MCF 7 CELL LINE; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; CDC25 PHOSPHATASES; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; HEP G2 CELLS; HT29 CELLS; HUMANS; IMIDAZOLES; MCF-7 CELLS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASMS, EXPERIMENTAL; PYRIDAZINES; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 84902185122     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.05.063     Document Type: Article

References (33)

1. C.J. Sherr Cancer cell cycles Science 74 1996 1672 1677
2. G. Evan, and K.H. Vousden Proliferation, cell cycle and apoptosis in cancer Nature 411 2001 342 348
3. C. Golias, A. Charalabopoulos, and K. Charalabopoulos Cell proliferation and cell cycle control: a mini review Int. J. Clin. Pract. 58 2004 134 141
4. K. Vermeulen, D. Van Bockstaele, and Z. Berneman The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer Cell Prolif. 36 2003 131 149
5. M. Park, and S. Lee Cell cycle and cancer J. Biochem. Mol. Biol. 36 2003 60 65
6. M. Malumbres, and M. Barbacid To cycle or not to cycle: a critical decision in cancer Nat. Rev. Cancer 1 2001 222 231
7. C. Karlsson-Rosentha, and J. Millar Cdc25: mechanisms of checkpoint inhibition and recovery Trends Cell Biol. 16 2006 285 292
8. A. Lindqvist, H. Källström, A. Lundgren, E. Barsoum, and C.K. Rosenthal Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome J. Cell Biol. 171 2005 35 45
9. B.G. Gabrielli, C.P. De Souza, I.D. Tonks, J.M. Clark, N.K. Hayward, and K.A. Ellem Cytoplasmic accumulation of CDC25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells J. Cell Sci. 109 1996 1081 1093
10. C.P. De Souza, K.A. Ellem, and B.G. Gabrielli Centrosomal and cytoplasmic Cdk2/cyclin B1 activation precedes nuclear mitotic events Exp. Cell Res. 257 2000 11 21
11. B.G. Gabrielli, J.M. Clark, A.K. McCormack, and K.A. Ellem Hyperphosphorylation of the N-terminal domain of cdc25 regulates activity toward cyclinB1/cdc2 but not cyclin A/cdk2 J. Biol. Chem. 272 1997 28607 28614
12. M.O. Contour-Galcéra, O. Lavergne, M.C. Brezak, B. Ducommun, and G. Prévost Synthesis of small molecule CDC25 phosphatases inhibitors Bioorg. Med. Chem. Lett. 14 2004 5809 5812
13. S.W. Ham, H.J. Park, and D.H. Lim Studies on menadione as an inhibitor of the cdc25 phosphatase Bioorg. Chem. 25 1997 33 36
14. H. Park, Y.J. Bahn, S.K. Jung, D.G. Jeong, S.H. Lee, I. Seo, T.S. Yoon, S.J. Kim, and S.E. Ryu Discovery of novel Cdc25 phosphatase inhibitors with micromolar activity based on the structure-based virtual screening J. Med. Chem. 51 2008 5533 5541
15. N. Delaet, N. Ohmawari, H. Nakai, Preparation of 4,5-Diaryl-1,2,4- triazole-3-thiones and Analogs as Sphingomyelinase Inhibitors. From PCT Int. Appl., WO 2002066447 A1 20020829, 2002.
16. X. Li, P. Zhan, H. Liu, D. Li, L. Wang, X. Chen, H. Liu, C. Pannecouque, J. Balzarini, E. De Clercq, and X. Liu Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors Bioorg. Med. Chem. 20 2012 5527 5536
17. R. Boutros, V. Lobjois, and B. Ducommun CDC25 phosphatases in cancer cells: key players? Good targets? Nat. Rev. Cancer 7 2007 495 507
18. I. Blomberg, and I. Hoffmann Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases Mol. Cell. Biol. 19 1999 6183 6194
19. I. Hoffmann, G. Draetta, and E. Karsenti Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition EMBO J. 13 1994 4302 4310
20. S. Jinno, K. Suto, A. Nagata, M. Igarashi, Y. Kanaoka, H. Nojima, and H. Okayama Cdc25A is a novel phosphatase functioning early in the cell cycle EMBO J. 13 1994 1549 1556
21. M. Molinari, C. Mercurio, J. Dominguez, F. Goubin, and G.F. Draetta Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis EMBO Rep. 1 2000 71 79
22. H. Zhao, J.L. Watkins, and H. Piwnica-Worms Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints Proc. Natl. Acad. Sci. U. S. A. 99 2002 14795 14800
23. G.K. Schwartz, and M.A. Shah Targeting the cell cycle: a new approach to cancer therapy J. Clin. Oncol. 23 2005 9408 9421
24. D. Sampath, Z. Shi, and W. Plunkett Inhibition of cyclin-dependent kinase 2 by the Chk1-Cdc25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine Mol. Pharmacol. 62 2002 680 688
25. J.E. Chipuk, and D.R. Green How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 18 2008 157 164
26. L. Lalier, P.F. Cartron, P. Juin, S. Nedelkina, S. Manon, B. Bechinger, and F.M. Vallette Bax activation and mitochondrial insertion during apoptosis Apoptosis 12 2007 887 896
27. L. Scorrano, and S.J. Korsmeyer Mechanisms of cytochrome c release by proapoptotic BCL-2 family members Biochem Biophys. Res. Commun. 304 2003 437 444
28. V. Petronilli, G. Miotto, M. Canton, R. Colonna, P. Bernardi, and F. Di Lisa Review imaging the mitochondrial permeability transition pore in intact cells Biofactors 8 1998 263 272
29. M. Brisson, C. Foster, P. Wipf, B. Joo, R.J. Tomko Jr., T. Nguyen, and J.S. Lazo Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone Mol. Pharmacol. 71 2007 184 192
30. J. Rudolph Redox regulation of the Cdc25 phosphatases Antioxid. Redox Signal 7 2005 761 767
31. G. Buhrman, B. Parker, J. Sohn, J. Rudolph, and C. Mattos Structural mechanism of oxidative regulation of the phosphatase Cdc25B via an intramolecular disulfide bond Biochemistry 44 2005 5307 5316
32. Y. Song, X. Guo, B. Zheng, X. Liu, X. Dong, L. Yu, and Y. Cheng Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity Toxicol. In Vitro 25 2001 937 943
33. J.J. Maoret, Y. Anini, C. Rouyer-Fessard, D. Gully, and M. Laburthe Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice Int. J. Cancer 80 1999 448 454